| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib inhibits tyrosine kinases such as BCR-ABL, c-KIT, and PDGFR, suppressing the aberrant signaling that drives cancer growth. It interrupts cell division and promotes apoptosis in cancer cells. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that interferes with RAF kinases and VEGFR-2, slowing tumor growth and inhibiting angiogenesis. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib blocks the activity of EGFR by competitively binding to its ATP-binding site, thus preventing downstream signaling and growth stimulation. | ||||||
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
Alectinib specifically inhibits ALK, a receptor tyrosine kinase, to suppress the signaling pathways involved in cell survival and proliferation, mainly in non-small cell lung cancer. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
ABT-199 disrupts the BCL-2 protein's anti-apoptotic function, leading to apoptosis induction in cancer cells, particularly effective against chronic lymphocytic leukemia (CLL). | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib also targets CDK4/6, hindering cell cycle progression in hormone receptor-positive breast cancer and enhancing the efficacy of endocrine therapies. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib inhibits CDK4/6, regulating cell cycle progression and replication in HR-positive, HER2-negative advanced breast cancers. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib is a JAK1/2 inhibitor that interrupts cytokine signaling pathways in myeloproliferative disorders, reducing inflammation and controlling abnormal cell growth. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib targets Bruton's tyrosine kinase (BTK), impeding B-cell receptor signaling and promoting apoptosis in B-cell malignancies, notably effective in chronic lymphocytic leukemia. | ||||||